Important pharmacy news and late-breaking industry information updated daily.
On Monday, March 25, APhA delegates met at Washington State Convention Center in Seattle for the final session of the APhA House of Delegates (HOD) during the 2019 APhA Annual Meeting & Exposition. The delegates deliberated and voted on remaining proposed policy from the APhA Policy Reference Committee on consolidation within health care, and new business items related to gluten content in medications, unit-of-use packaging, pharmacy technician scope, and working with patients with special needs, but it was pharmacy staff safety and well-being, as well as recognition of pharmacists as practitioners and within collaborative practice that took center stage.
There have been 387 confirmed cases of measles in the United States so far this year, a figure that is higher than the full-year total for 2018 and the second-highest total since measles was declared eliminated in this country in 2000, CDC said Monday.
FDA on Friday approved cladribine (Mavenclad—EMD Serono) tablets for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including relapsing-remitting disease and active secondary progressive disease. The drug is not recommended for MS patients with clinically isolated syndrome.
Fentanyl-related overdose deaths in the United States have increased by more than 1,000% from 2011 through 2016, according to a startling new CDC report.
In the past, aspirin was viewed almost as a wonder drug for preventing a plethora of diseases, cancers, and cardiac and neurological events. But in recent years, numerous studies have called into question the utility of aspirin for primary prevention.
Influenza activity continues to be high in the United States, with a growing proportion of activity due to influenza A(H3N2) viruses, continued circulation of influenza A(H1N1) viruses, and low levels of influenza B viruses, CDC warned Thursday.
FDA on Wednesday approved testosterone undecanoate (Jatenzo—Clarus Therapeutics), an oral testosterone capsule for the treatment of men with certain forms of hypogonadism.
FDA on Tuesday approved siponimod (Mayzent—Novartis) tablets for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Icosapent ethyl (Vascepa—Amarin) may be more effective in preventing ischemic events than previously reported. The drug significantly reduced not only first but subsequent cardiovascular events among high-risk patients already receiving statin therapy, according to results of REDUCE-IT, presented at the American College of Cardiology’s (ACC) 68th Annual Scientific Session.
Bayer and Johnson & Johnson have agreed to pay $775 million to settle about 25,000 lawsuits involving the blood thinner rivaroxaban (Xarelto), which they jointly sell.